We previously demonstrated that DNA-polylactic-polyglycolic acid (PLGA)-coated stents can deliver genes to the arterial wall with reporter expression involving 1% of neointimal cells. The present study investigated a novel formulation utilizing denatured collagen in DNA-stent coatings; denatured collagen was hypothesized to enhance gene transfer due to adhesion molecule interactions and actinrelated mechanisms. Arterial smooth muscle cells (SMCs) cultivated on denatured collagen had significantly greater plasmid DNA (b-galactosidase) transfection than SMC grown on native collagen (18.371.2 vs 1.070.1%, Po0.001). The denatured-collagen effect was completely blocked with antia v b 3 integrin antibody. SMCs cultivated on native collagen supplemented with tenascin-C (TN-C), a protein recognized by a v b 3 integrins, showed a 33-fold increase in transfection compared to control (Po0.001); this effect was also blocked with anti-a v b 3 antibody. We observed that cells grown on denatured collagen had marked F-actin-enriched stress fibers and intense perinuclear G actin, compared to those grown on native collagen, which demonstrated F-actinenriched focal adhesions without perinuclear G-actin localization. Cytochalasin-D, an F actin depolymerizing agent, caused significantly increased SMC transfection in cells cultivated on native collagen compared to control cells (18.071.8 vs 3.0270.9%, Po0.001) further supporting the view that actin-related cytoskeletal changes influence transfection. A denatured-collagen-PLGA composite vascular stent coating similarly resulted in increased plasmid DNA green fluorescent protein (GFP) expression compared to controls (Po0.001) in SMC cultures; the increased transfection was blocked by anti-a v b 3 antibody. Pig coronary studies comparing denatured-collagen-PLGA-coated stents containing plasmid DNA (encoding GFP) to coated stents without DNA demonstrated 10.8% of neointimal cells transfected; this level of expression was almost an order of magnitude greater than previously reported with a DNA delivery stent. It is concluded that denatured collagen incorporated into plasmid DNA-stent coating formulations may increase the level of gene expression in vitro and in vivo because of integrin-related mechanisms and associated changes in the arterial smooth muscle cell actin cytoskeleton.
caused significantly increased SMC transfection in cells cultivated on native collagen compared to control cells (18.071.8 vs 3.0270.9%, Po0.001) further supporting the view that actin-related cytoskeletal changes influence transfection. A denatured-collagen-PLGA composite vascular stent coating similarly resulted in increased plasmid DNA green fluorescent protein (GFP) expression compared to controls (Po0.001) in SMC cultures; the increased transfection was blocked by anti-a v b 3 antibody. Pig coronary studies comparing denatured-collagen-PLGA-coated stents containing plasmid DNA (encoding GFP) to coated stents without DNA demonstrated 10.8% of neointimal cells transfected; this level of expression was almost an order of magnitude greater than previously reported with a DNA delivery stent. It is concluded that denatured collagen incorporated into plasmid DNA-stent coating formulations may increase theIntroduction Plasmid DNA delivery from intravascular stents 1 is a forefront approach for achieving gene therapy for cardiovascular disease. Controlled release of DNA from vascular stents was previously investigated by our group in a series of studies using green fluorescent protein (GFP) plasmid DNA incorporated into a polylacticpolyglycolic acid copolymer (PLGA) emulsion coating on stainless-steel stents. 1 These studies demonstrated GFP expression in cultured vascular SMCs, as well as in pig coronary arteries, with 1% of neointimal arterial smooth muscle cells transfected. Although these results demonstrated great promise, the relatively low level of transfection achieved in this initial study would likely preclude therapeutic efficacy. Therefore, the present paper focused on a mechanistic approach toward enhancing the level of transfection with DNA-delivery stents.
Prior investigations have demonstrated that specific cell adhesion receptors, including integrin heterodimers, can be used to target uptake of either plasmid DNA 2, 3 or viral 4, 5 vectors. However, these studies did not examine whether the addition of exogenous ligands to the extracellular matrix (ECM) affected gene expression efficiency. Previous studies 6 have demonstrated that denatured type I collagen, but not native collagen, can upregulate Tenascin C (TN-C) in arterial smooth muscle cells (SMCs). TN-C is an ECM protein that enhances cell survival and proliferation. 7, 8 Furthermore, this denatured collagen-SMC interaction can be blocked with an anti-b3 integrin antibody, 6, 9 thereby indicating a specific integrin receptor interaction is responsible for this effect. In this study, we attempted to determine whether specific ECM-integrin interactions involving denaturedcollagen coatings and associated actin-cytoskeletal changes would increase the extent of plasmid DNA transfection. We hypothesized that denatured-collagen coatings on a DNA-delivery stent could lead to an increased level of arterial gene expression from DNAdelivery stents.
The present study investigated DNA-controlled release using denatured collagen as a component of a DNA-delivery stent coating to hypothetically increase the level of plasmid DNA transfection through mechanisms involving b 3 integrin receptor interactions and associated changes in actin dynamics. The goals of our investigations were:
(1) To investigate the effects of a denatured-collagen substrate (an a v b 3 integrin ligand) on plasmid DNA transfection in cell culture, compared to a native type I collagen substrate (2) To determine if the observed transfection was related to b 3 integrin interactions; (3) To learn if TN-C, an alternative a v b 3 integrin ligand, could also positively influence transfection efficiency in cell culture (4) To examine changes in the F and G-actin cytoskeletal distribution due to denatured collagen in culture, and to determine whether actin-specific agents affect transfection (5) To formulate and characterize a coating that includes denatured collagen for use in a DNAcontrolled release stent to deliver plasmid DNA to pig coronary arteries
Results

SMC cultivated on denatured vs native collagen demonstrate higher levels of transfection
When A10 cells were cultured on denatured collagen (Figure 1b ), they demonstrated a 17-fold greater bgalactosidase transfection level then did A10 cells grown on native collagen (Figure 1a) Figure 1e ), or on cell growth.
Next, we determined whether the a v b 3 integrindependent effects on enhanced transfection were specific for SMC interactions with denatured collagen, or whether alternate a v b 3 integrin ligands (ie TN-C) would also affect the efficiency of transfection. Addition of TN-C to a native collagen substrate resulted in a dosedependent increase in transfection (Figure 2a ). However, while the lowest dose of TNC-C used, 1-mg/ml, had no effect on transfection efficiency (Figure 2a) , it resulted in a three-fold increase in proliferation per WST-1 assay (data not shown). This suggests that although TN-C also caused increased SMC proliferation in these studies, enhanced transfection and proliferation are independent events. The highest dose of TN-C used, 50-mg/ml, caused a 33-fold increase in transfection efficiency with only an associated seven-fold increase in proliferation (data not shown). Furthermore, like denatured-collagen-mediated transfection, the TN-C-mediated transfection enhancement was found to be a v b 3 dependent. Blocking antibody studies using either anti-a v b 3 or anti-b 3 or reduced transfection to levels seen without the addition of TN-C (Figure 2b ).
Actin changes associated with increased transfection in vitro
Since changes in cell interactions with ECM via integrins ultimately control intracellular actin dynamics, we next investigated the relation between cellular DNA uptake and the cytoskeletal distribution of the different forms of actin. Double fluorescent label studies were performed using phalloidin (rhodamine) as a marker of F actin, and nuclease-I (FITC) as a marker of G-actin. Cells grown on native collagen were somewhat elongated and displayed prominent colocalization of F and G actins in focal adhesions in confocal images (Figure 3a ). In A10 cell cultures grown on denatured collagen, we also observed a marked qualitative increase in G-actin intensity and concentration around the nucleus (Figure 3b ), and prominent F-actin stress fibers, not noted in native collagen cultures.
Having shown an association between cell substrate, actin depolymerization (G actin), and transfection capacity, we sought to perform experiments to investigate a potential causal relation between manipulation of the actin cytoskeleton and transfection capacity. The F-actin 
Denatured-collagen stent-coating formulation
Having demonstrated in cultured SMCs that denatured collagen enhances the transfection efficiency of plasmid DNA, we next carried out experiments in which plasmid DNA and denatured collagen were formulated as a coating on vascular stents. It should be noted that native collagen gels, because of their fragile nature, proved to be unsuitable for stent coatings; these preparations broke up upon stent deployment with immediate shedding of the native collagen coating. Thus, no native collagen control group was possible for the in vivo studies.
In the present study, crown stents (Cordis, Morristown, NJ, USA) were coated with several formulations, comparing DNA dispersed in denatured collagen, to the same coating, but with an outer PLGA polymer-coating layer. These studies demonstrated (Figure 5a ) that the release rate of plasmid DNA from the denaturedcollagen-only coating was far too rapid for potential in vivo use, with virtually all of the DNA released in less than 30 min. However, successively increasing concentrations of an outer PLGA coating resulted in a more sustained release of DNA, with a release duration of more than 24 h (Figure 5a ). In addition, it was necessary to crosslink the denatured-collagen coatings in order to retain these coatings as a stable robust surface layer on the vascular stents. Thus, all denatured-collagen-coated stents were treated with water-soluble carbodiimide. The plasmid DNA released from these formulations in sustained elution studies was intact, as demonstrated by agarose gels (Figure 5b) .
A series of cell culture studies was carried out with vascular stents coated with the DNA-denatured collagen, plus PLGA. We observed transfection localized only to cells in culture in contact with the stent struts (data not shown), and thus confined our observations to those areas. In these experiments, we also sought to learn if the a v b 3 integrin was involved, especially since the coating formulation involved crosslinking denatured collagen followed by coating with PLGA, and thus differed markedly from the puredenatured type I collagen cell culture substrates studied in the earlier experiments. Nevertheless, A10 cell culture blocking antibody studies using monoclonal anti-a v b 3 demonstrated significant inhibition of the a v b 3 enhanced transfection associated with the denatured-collagen-PLGA coating (Figure 5c ). However, the relative magnitude of the transfection in vitro with denatured-collagen-PLGA stents, and its inhibition, was less than that observed with A10 cells plated directly on the collagen substrates, indicating the likely influence of other formulation steps involving the PLGA and crosslinking procedures. Nevertheless, this particular formulation demonstrated enhanced transfection in cell culture compared to controls, and furthermore, unlike native collagen, was suitable as a stent coating for intravascular studies with DNAdelivery stents.
Denatured collagen enhances DNA delivery from coronary stents in vivo GFP expression levels in the arterial wall with denatured-collagen-PLGA-coated stents exhibited high levels of GFP fluorescence expression in the neointima (Figures 6a-c vs control artery 6d) , which was confirmed by GFP immunohistochemistry (Figure 6e vs control artery 6f). Denatured-collagen-PLGA-coated stents in the present studies containing 500 mg DNA demonstrated 10.471.23% neointimal cells expressing GFP. Coated stents without plasmid DNA (controls) demonstrated no evidence of GFP expression (Figure 6d ). 1,12 b 3 and a v b 3 integrins were shown by others to be upregulated in SMCs after vascular injury. 13, 14 Accordingly, SMC a v b 3 integrin interactions with the ECM have been widely investigated in tissue culture and in vivo in order to define their role in SMC proliferation and migration mechanisms. 13, 15, 16 In the present study, our working hypothesis was that these same a v b 3 integrin interactions could also be involved in regulating plasmid-DNA transfection. Our integrinblocking antibody results strongly support this ( Figures  1e, 2b, 5c ). Receptor signaling 9 is involved in mediating cytoskeletal changes such as those observed in the present studies. Our data also indicate that actincytoskeletal changes may be in part responsible for the increased transfection of SMCs cultivated on either denatured collagen or TN-C-enriched substrates compared to native collagen. We hypothesized that modification of the G-/F-actin cytoskeletal distribution might play a role in increasing transfection. G actin is an inhibitor of nuclease-I. 17 Thus, switching the cytoskeleton balance in favor of G actin or modifying the cellular actin distribution (see Figure 3b ) might enhance DNA transfection based on decreased plasmid destruction.
Could the increased transfection observed in these studies be somehow related to increased proliferation observed on some of the substrates, such as denatured collagen or TN-C? The results of our cytochalasin-D experiments indicate that proliferation may not be involved in the mechanisms responsible for the observed increase in transfection (Figure 4b ). In these studies, although there were no significant differences in proliferation comparing SMCs grown on native collagen to those grown on native collagen with added cytochalasin-D (see Results, above), there was significantly greater transfection (18 vs 2%) in the cytochalasin-D-treated group (Figure 4b ), indicating that an actin-related mechanism may be a critical component, and that cellular proliferation-related events are occurring independently of transfection-enhancement mechanisms. This view was further confirmed through studies using the F-actin stabilizing agent, jasplakonilide, which blocked the cytochalasin-D-related increase in transfection (Figure 4b ), thus providing support for an actinrelated mechanism being responsible for the observed increased transfection.
A previous study by our group using a pig coronary stent angioplasty model demonstrated successful coronary artery gene transfer with a plasmid DNA delivery stent using a PLGA emulsion coating, 1 but with far less neointimal expression (1%) than observed in the present study (10.4%). These very different results arose from similar study designs: The same vector was used in both studies; comparable DNA loadings were used in both; an identical PLGA component was used in both stent formulations; both studies used Crown Stents; the animal strain, size, sex, and supplier were the same; the study durations were identical; and the operating team included all the same individuals. However, direct comparisons with our previous study 1 are not possible. Nevertheless, the increased transfection noted the present report suggests that the denatured-collagen component of the coating may have been responsible for the relatively greater transfection than that observed previously. 1 At this time, no other researchers have reported results with plasmid DNA delivery stents.
In conclusion, the present results support the view that plasmid DNA delivery from stent coatings containing a v b 3 integrin ligands, such as denatured collagen, may result in increased levels of arterial SMC transgene expression. Overall, our data indicate that this may be due to integrin-signaling mechanisms, and associated G-actin-related cytoskeletal changes. a b Figure 3 Changes in the arterial smooth muscle cell cytoskeletal actin distribution in A10 cells cultivated on native and denatured collagen. Double-fluorescent label studies of F and G actins were performed using phalloidin (rhodamine) as a marker of F actin, and nuclease-I (FITC) as a marker of G actin. Cells grown on native collagen (a) were relatively elongated and displayed prominent colocalization of F and G actins in focal adhesions in confocal images, while on denatured collagen (b), there was a marked qualitative increase in G-actin intensity and concentration both in the cytoplasm and around the nucleus, with prominent F-actin stress fibers at the cell perimeter. Confocal fluorescent photomicrographs, Â 400.
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Materials and methods
Collagen preparation
Native collagen: Type I collagen (3.1 mg/ml, Vitronectin 100, Cohesion Technologies, Palo Alto, CA, USA) was neutralized with 0.1 N NaOH and 10 Â PBS to a concentration of 2.5 mg/ml, and gelled at 371C according to the manufacturer's directions. Denatured Collagen: Type I collagen was acidified with 0.17% glacial acetic acid (v/v), boiled for 1 h, then neutralized as above. Denatured collagen was allowed to air-dry on the desired surface. In experiments testing the effect of TN-C (Gibco) on transfection, TN-C was mixed into the native collagen solution at the indicated concentrations prior to well coating, and gelled at 371C.
Transfection in vitro
A fetal rat arterial SMC line (A10, American Type Culture Collection, Rockville, MD, USA) utilized in previous studies modeling gene-delivery stents 1, 12 was used for all tissue culture experiments, and was routinely maintained in growth medium consisting of M199 (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS, Hyclone, Logan UT), 100 U/ml penicillin, and 100 mg/ml streptomycin (PS, Gibco). A10 Integrin blocking A10 cells were pretreated with either mouse monoclonal anti-rat b 3 integrin IgG (25 mg/ml, CD61*, PharMingin, San Diego, CA, USA), mouse monoclonal anti-human a v b 3 integrin IgG (15 mg/ml, LM609, Chemicon, Temecula, CA, USA), or with equivalent concentration of nonimmune mouse IgG* (Pierce, Rockford, IL, USA) at the time of plating as previously described 9 (*sodium azide was removed by microdialysis (Slide-A-Lyzer, MWCO 10 kDa, Pierce, Rockford, IL, USA)). Cells were suspended at 1 Â 10 5 cells/ml in growth medium containing the antibody, and then plated. Incubations and transfection then proceeded in the same manner as for nontreated cells.
b-Galactosidase expression
Medium was aspirated from cultures, which were then fixed with 4% paraformaldehyde. This in turn was rinsed twice from the cultures with 2 mM MgCl 2 in PBS, and replaced with X-gal stain. 18 Cultures were incubated overnight at 371C, and then washed three times with PBS. The total number of cells and the number staining positive for X-gal were visually counted per Â 100 field, and the per cent positive per well determined from the mean of 10 fields per well.
Cell attachment, proliferation, and viability
Triplicate cultures plated under conditions as described were incubated in six-well plates for 5 h at 371C prior to visual counting of cells attached in at least three Â 100 fields (10.7 mm 2 ) per well for quantification of attachment. Cell number per mm 2 was again determined in this manner at 72 h after treatments as described. Cell 
Double-fluorescent labeling
Cells were fixed with 4% paraformaldeyde at 6 h. Cultures were then stained for either F or G actin (Rhodamine 514 phalloidin, or Oregon green 488 Deoxyribonuclease I, respectively, Molecular Probes), following permeabilization and blocking, according to the manufacturer's directions. Cultures were then mounted using Vectashield mounting medium containing 4,6-diamidino-2-phenylindole mount (DAPI, Vector Labs, Burlingame, CA, USA) for visualization of nuclei, and confocal images recorded using a Leica TCS4D confocal microscope at Â 400 magnification.
Cytoskeletal manipulation
Cells were allowed to adhere to native collagen-coated six-well plates as above, then growth medium was replaced by serum-free M199, and transfection with plasmid allowed to proceed for 3-5 h. The medium was changed again to M199/2% FBS containing either 10 mM Jasplakinolide (jas, Molecular Probes) or 0.7% methanol (vehicle). Cells were incubated for 30 min and medium again replaced with M199, without or with 100 nM cytocholasin-D (cytoD, Sigma, St Louis, MO, USA) for an additional 30 min. After another medium change to remove jas or cytoD, incubations proceeded in the same manner as for nontreated cells, in M199/2% FBS, and transfection evaluated at 72 h. In order to evaluate the effect of cytoskeletal manipulation with jas and cytoD on the growth of the cells on collagen, cells were plated as above on native collagen and treated with cytoD or jas as above. After the treatments, the medium was replaced with growth medium for 72 h and assayed with WST-1 as above.
Stent-coating formulation
Denatured collagen was mixed with 10% (w/w) 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (Sigma, St Louis, MO, USA) as a crosslinking agent to achieve a robust coating. This mixture was incubated at 371C for 30 min prior to use as a stent coating. GFP Plasmid DNA (pEGFP-N3, Clontech, Palo Alto, CA, USA) was added to the above collagen solution and stored at 41C. The formulation was such that fully coated stents carried 500 mg DNA. The mixture was applied in 10 ml increments under sterile conditions onto the stent surface of 15 mm Crown stents (Cordis, Warren, NJ, USA), with manual rotation, to form a thin, uniform coating, and dried at 371C under vacuum. The procedure was repeated until a total of 400 ml (1 mg of collagen) was coated per stent. Coated stents were dipped briefly in 100 mg/ml PLGA (MW 50 000, Birmingham Polymers, Birmingham, AL, USA) and air-dried. This thin coating was shown to be optimal for preventing rapid DNA release by preliminary experiments in which in vitro DNA release from stents coated with designated concentrations of PLGA was characterized. Collagen-plasmid DNA-coated stents were shaken in 100 ml TE buffer (pH 7.4) at 371C. Buffer was removed and replaced with fresh buffer after 0.5, 1, 2, 3, 7, and 24 h of shaking. The DNA concentrations in the collected buffers were determined by UV spectrometry (GeneQuantPro, Amersham Pharmacia Biotech), and checked for structural integrity by running 0.3 mg/lane on an agarose gel in comparison to untreated plasmid.
Transfection via stent in vitro
A10 SMCs were prepared in uncoated six-well plates as described above, prior to transfection. Coated stents were incubated in 300 ml serum-free medium at 371C for 20-30 min with the addition of 5 ml Lipofectin (GIBCO) for 15 min. After aspiration of medium from the cell cultures, stents and their incubation medium, diluted to 1 ml, were transferred to the cell cultures and incubated at 371C for 5 h. FBS was then added to a final concentration of 5%, and changed to growth medium after 24 h. After fixation, cultures were DAPI mounted for visualization of nuclei, and total cell number determined per Â 200 field in immediate contact with the stent. GFP-expressing cells were also visually counted in the same fields, and results reported as the percentage of cells transfected (mean7s.e.) of at least five fields per culture in replicate cultures.
Transfection via stent: in vivo
Animal experiments were conducted with the approval of the Institutional Animal Care and Use Committee of the Children's Hospital of Philadelphia. Denaturedcollagen-PLGA-coated stents (either with GFP-plasmid loading or control without vector), prepared as described above, were deployed using two stents per animal in both the left ascending or left circumflex coronary arteries (LAD, LCX) of seven normal Yorkshire swine as previously described by our group.
1 Animals were euthanized after 7 days and representative samples of stented arteries, arterial segments distal to the stents, and unstented control pig coronary arteries were prepared for morphology studies by first removing the stent from the arteries and then embedding in frozen section media (O.C.T., Tissue-Tek, Torrance, CA, USA). The percentage of GFP-positive cells, normalizing for DAPI-positive cells, in representative frozen sections of each of the 14 stented arteries and nonstented arteries was determined according to previously published methodology, separately reporting neointimal and medial expression. 1, 12 GFP expression was confirmed with anti-GFP immunohistochemistry, 1, 12 and hematoxylin and eosin sections were prepared for routine light microscopy.
Statistical analysis
Data for all experiments were expressed as means plus or minus the standard error of the mean (s.e.). The significance of differences was assessed using Student's t-test, and was termed significant when Pr0.05.
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